CN1528315A - 治疗糖皮质素功能失调相关性精神病的方法 - Google Patents

治疗糖皮质素功能失调相关性精神病的方法 Download PDF

Info

Publication number
CN1528315A
CN1528315A CNA200410039908XA CN200410039908A CN1528315A CN 1528315 A CN1528315 A CN 1528315A CN A200410039908X A CNA200410039908X A CN A200410039908XA CN 200410039908 A CN200410039908 A CN 200410039908A CN 1528315 A CN1528315 A CN 1528315A
Authority
CN
China
Prior art keywords
psychosis
psychotic
antagonist
glucocorticoid
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200410039908XA
Other languages
English (en)
Chinese (zh)
Inventor
A��F��ɳ�IJ���
A·F·沙茨伯格
��˹��ŵ��
J·K·贝拉诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN1528315A publication Critical patent/CN1528315A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200410039908XA 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法 Pending CN1528315A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
US60/060,973 1997-10-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB988097923A Division CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006101003657A Division CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Publications (1)

Publication Number Publication Date
CN1528315A true CN1528315A (zh) 2004-09-15

Family

ID=22032889

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA200410039908XA Pending CN1528315A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法
CNB988097923A Expired - Fee Related CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
CNA2006101003657A Pending CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB988097923A Expired - Fee Related CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
CNA2006101003657A Pending CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Country Status (17)

Country Link
US (2) US6150349A (https=)
EP (1) EP1023074B1 (https=)
JP (3) JP2001518509A (https=)
KR (2) KR100840957B1 (https=)
CN (3) CN1528315A (https=)
AT (1) ATE332696T1 (https=)
AU (1) AU747956B2 (https=)
CA (1) CA2302586C (https=)
CY (1) CY1106330T1 (https=)
DE (1) DE69835225T2 (https=)
DK (1) DK1023074T3 (https=)
ES (1) ES2268792T3 (https=)
IL (2) IL135469A0 (https=)
NO (1) NO327233B1 (https=)
NZ (1) NZ503250A (https=)
PT (1) PT1023074E (https=)
WO (1) WO1999017779A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063526A1 (fr) * 2004-12-15 2006-06-22 Shanghai Three-Alliance Biotechnologies Co., Ltd. Utilisation de la cymipristone pour le traitement de la depression

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
US7071328B2 (en) * 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
CA2454339C (en) 2001-07-23 2012-01-10 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
NZ531477A (en) * 2001-08-31 2006-10-27 Corcept Therapeutics Inc Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome
DE60230936D1 (de) * 2001-10-26 2009-03-05 Organon Nv Verwendung von (11beta, 17beta)-11-(1,3-Benzodioxol-5-yl)-17-Hydroxy-17-(1-Propinyl)-estra-4,9-dien-3-on zur Behandlung von schweren Depressionen
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
JP2005535664A (ja) * 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
JP2006516651A (ja) * 2003-02-04 2006-07-06 コーセプト セラピューティクス， インコーポレイテッド 産後精神病の処置のための抗糖質コルチコイド
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
WO2007131041A2 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
WO2008157460A1 (en) * 2007-06-15 2008-12-24 Cook, Kevin, M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
WO2011150209A1 (en) * 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
WO2012106514A2 (en) 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
KR20180008627A (ko) * 2015-05-18 2018-01-24 코어셉트 쎄라퓨틱스, 잉크. 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법
CN114680890A (zh) * 2016-10-21 2022-07-01 西铁城时计株式会社 检测装置
EP4653047A3 (en) 2019-03-18 2026-02-18 Nieman, Lynnette K. Mifepristone for use in improving insulin sensitivity
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
EP0954317B1 (en) * 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063526A1 (fr) * 2004-12-15 2006-06-22 Shanghai Three-Alliance Biotechnologies Co., Ltd. Utilisation de la cymipristone pour le traitement de la depression

Also Published As

Publication number Publication date
NO327233B1 (no) 2009-05-18
PT1023074E (pt) 2006-12-29
CA2302586C (en) 2008-06-10
DE69835225T2 (de) 2007-07-05
KR100840957B1 (ko) 2008-06-24
AU9683298A (en) 1999-04-27
KR100804558B1 (ko) 2008-02-20
JP5180125B2 (ja) 2013-04-10
US6362173B1 (en) 2002-03-26
CA2302586A1 (en) 1999-04-15
DE69835225D1 (de) 2006-08-24
DK1023074T3 (da) 2006-11-06
KR20010024431A (ko) 2001-03-26
NO20001744L (no) 2000-04-05
IL135469A0 (en) 2001-05-20
NO20001744D0 (no) 2000-04-05
CN1919199A (zh) 2007-02-28
CN1272788A (zh) 2000-11-08
JP2001518509A (ja) 2001-10-16
AU747956B2 (en) 2002-05-30
IL135469A (en) 2007-03-08
KR20070032822A (ko) 2007-03-22
ATE332696T1 (de) 2006-08-15
EP1023074B1 (en) 2006-07-12
US6150349A (en) 2000-11-21
JP2009132743A (ja) 2009-06-18
JP2009051858A (ja) 2009-03-12
NZ503250A (en) 2001-09-28
CY1106330T1 (el) 2011-10-12
WO1999017779A1 (en) 1999-04-15
CN1187053C (zh) 2005-02-02
EP1023074A1 (en) 2000-08-02
ES2268792T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
CN1528315A (zh) 治疗糖皮质素功能失调相关性精神病的方法
CN1130200C (zh) 用于治疗痴呆的糖皮质激素受体拮抗剂
JP2009102343A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
UA100119C2 (uk) Застосування 3-альфа-андростандіолу в поєднанні з агоністом 5-ht1а для лікування сексуальної дисфункції
CN1820756A (zh) 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
CN1658883A (zh) 提高电休克治疗疗效的方法
EP2694065B1 (en) Composition for treating hypoactive sexual desire disorder
BR112015002687A2 (pt) regimes de tratamento
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
US20180289655A1 (en) Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases
WO2008047983A1 (en) Composition for preventing and treating inflammatory bowel diseases
JP2009102346A (ja) グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
HK1104214A (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
CN121221609A (zh) 一种葡萄糖神经酰胺合成酶激活剂在制备预防和/或治疗焦虑的药物中的用途
CN117580576A (zh) Luvadaxistat用于治疗认知损害的用途
Lunenfeld PL1–01
CN1853638A (zh) 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication